Arrowhead Pharmaceuticals Completes Patient Enrollment In Its Global Phase 3 YOSEMITE Clinical Study Of Zodasiran To Treat Homozygous Familial Hypercholesterolemia

뉴스 본문을 불러오고 있어요.

Arrowhead Pharmaceuticals Completes Patient Enrollment In Its Global Phase 3 YOSEMITE Clinical Study Of Zodasiran To Treat Homozygous Familial Hypercholesterolemia | 웨이프 WAPE

Arrowhead Pharmaceuticals Completes Patient Enrollment In Its Global Phase 3 YOSEMITE Clinical Study Of Zodasiran To Treat Homozygous Familial Hypercholesterolemia

기사 요약

관련 종목

댓글 —